{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T04:47:48Z","timestamp":1666846068965},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11596-022-2623-3","type":"journal-article","created":{"date-parts":[[2022,10,16]],"date-time":"2022-10-16T23:02:20Z","timestamp":1665961340000},"page":"1071-1078","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Myeloid-derived Suppressor Cells Activate Liver Natural Killer Cells in a Murine Model in Uveal Melanoma"],"prefix":"10.1007","volume":"42","author":[{"given":"Yuan-yuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang-ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"San-qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang-liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-qiang","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"issue":"4","key":"2623_CR1","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1001\/jamaophthalmol.2013.2547","volume":"131","author":"HE Grossniklaus","year":"2013","unstructured":"Grossniklaus HE. Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture. JAMA Ophthalmol, 2013,131(4):462\u2013469","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"2623_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1615\/CritRevImmunol.2021037197","volume":"41","author":"T Jako\u0161","year":"2021","unstructured":"Jako\u0161 T, Pi\u0161lar A, Jewett A, et al. Myeloid-Derived Suppressor Cells Hamper Natural Killer Cell Activity in Cancer: Role of Peptidases. Crit Rev Immunol, 2021,41(2):77\u201399","journal-title":"Crit Rev Immunol"},{"issue":"1","key":"2623_CR3","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12885-019-5712-3","volume":"19","author":"NM Jones","year":"2019","unstructured":"Jones NM, Yang H, Zhang Q, et al. Natural killer cells and pigment epithelial-derived factor control the infiltrative and nodular growth of hepatic metastases in an Orthotopic murine model of ocular melanoma. BMC Cancer, 2019,19(1):484","journal-title":"BMC Cancer"},{"issue":"4","key":"2623_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00281-018-0685-x","volume":"40","author":"S Guia","year":"2018","unstructured":"Guia S, Fenis A, Vivier E, et al. Activating and inhibitory receptors expressed on innate lymphoid cells. Semin Immunopathol, 2018,40(4):331\u2013341","journal-title":"Semin Immunopathol"},{"issue":"10","key":"2623_CR5","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.2217\/imt.11.102","volume":"3","author":"A Malhotra","year":"2011","unstructured":"Malhotra A, Shanker A. NK cells: immune crosstalk and therapeutic implications. Immunotherapy, 2011,3(10):1143\u20131166","journal-title":"Immunotherapy"},{"issue":"3","key":"2623_CR6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov, 2020,19(3):200\u2013218","journal-title":"Nat Rev Drug Discov"},{"key":"2623_CR7","doi-asserted-by":"publisher","first-page":"638841","DOI":"10.3389\/fimmu.2021.638841","volume":"12","author":"N Tumino","year":"2021","unstructured":"Tumino N, Di Pace AL, Besi F, et al. Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT. Front Immunol, 2021,12:638841","journal-title":"Front Immunol"},{"issue":"5","key":"2623_CR8","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","volume":"54","author":"S Hegde","year":"2021","unstructured":"Hegde S, Leader AM, Merad M. MDSC: Markers, development, states, and unaddressed complexity. Immunity, 2021,54(5):875\u2013884","journal-title":"Immunity"},{"issue":"13","key":"2623_CR9","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.3390\/jcm10132872","volume":"10","author":"C Vanhaver","year":"2021","unstructured":"Vanhaver C, van der Bruggen P, Bruger AM. MDSC in Mice and Men: Mechanisms of Immunosuppression in Cancer. J Clin Med, 2021,10(13):2872","journal-title":"J Clin Med"},{"issue":"10","key":"2623_CR10","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.1182\/blood-2008-03-143776","volume":"112","author":"N Nausch","year":"2008","unstructured":"Nausch N, Galani IE, Schlecker E, et al. Mononuclear myeloid-derived \u201csuppressor\u201d cells express RAE-1 and activate natural killer cells. Blood, 2008,112(10):4080\u20134089","journal-title":"Blood"},{"key":"2623_CR11","doi-asserted-by":"publisher","first-page":"633205","DOI":"10.3389\/fimmu.2021.633205","volume":"12","author":"C Zalfa","year":"2021","unstructured":"Zalfa C, Paust S. Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy. Front Immunol, 2021,12:633205","journal-title":"Front Immunol"},{"issue":"10","key":"2623_CR12","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1182\/blood-2006-09-046201","volume":"109","author":"C Liu","year":"2007","unstructured":"Liu C, Yu S, Kappes J, et al. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood, 2007,109(10):4336\u20134342","journal-title":"Blood"},{"issue":"4","key":"2623_CR13","first-page":"212","volume":"13","author":"D Rusciano","year":"1993","unstructured":"Rusciano D, Lorenzoni P, Burger MM. Paracrine growth response as a major determinant in liver-specific colonization by in vivo selected B16 murine melanoma cells. Invasion Metastasis, 1993,13(4):212\u2013224","journal-title":"Invasion Metastasis"},{"issue":"2","key":"2623_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1076\/ceyr.18.2.125.5380","volume":"18","author":"CE Diaz","year":"1999","unstructured":"Diaz CE, Rusciano D, Dithmar S, et al. B16LS9 melanoma cells spread to the liver from the murine ocular posterior compartment (PC). Curr Eye Res, 1999,18(2):125\u2013129","journal-title":"Curr Eye Res"},{"issue":"6","key":"2623_CR15","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1167\/iovs.10-7067","volume":"52","author":"W Yang","year":"2011","unstructured":"Yang W, Li H, Mayhew E, et al. NKT cell exacerbation of liver metastases arising from melanomas transplanted into either the eyes or spleens of mice. Invest Ophthalmol Vis Sci, 2011,52(6):3094\u20133102","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2623_CR16","doi-asserted-by":"publisher","first-page":"111299","DOI":"10.1016\/j.biopha.2021.111299","volume":"137","author":"Z Wu","year":"2021","unstructured":"Wu Z, Zhang H, Wu M, et al. Targeting the NKG2D\/NKG2D-L axis in acute myeloid leukemia. Biomed Pharmacother, 2021,137:111299","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"2623_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/cmi.2016.28","volume":"14","author":"QF Zhang","year":"2017","unstructured":"Zhang QF, Yin WW, Xia Y, et al. Liver-infiltrating CD11b-CD27- NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression. Cell Mol Immunol, 2017,14(10):819\u2013829","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"2623_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12072-018-9909-3","volume":"13","author":"L Zhuang","year":"2019","unstructured":"Zhuang L, Fulton RJ, Rettman P, et al. Activity of IL-12\/15\/18 primed natural killer cells against hepatocellular carcinoma. Hepatol Int, 2019,13(1):75\u201383","journal-title":"Hepatol Int"},{"issue":"1","key":"2623_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.canlet.2013.04.029","volume":"336","author":"C Ni","year":"2013","unstructured":"Ni C, Wu P, Zhu X, et al. IFN-\u03b3 selectively exerts proapoptotic effects on tumor-initiating label-retaining colon cancer cells. Cancer Lett, 2013,336(1):174\u2013184","journal-title":"Cancer Lett"},{"issue":"22","key":"2623_CR20","doi-asserted-by":"publisher","first-page":"11005","DOI":"10.1158\/0008-5472.CAN-06-0811","volume":"66","author":"JJ Subleski","year":"2006","unstructured":"Subleski JJ, Hall VL, Back TC, et al. Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver. Cancer Res, 2006,66(22):11005\u201311012","journal-title":"Cancer Res"},{"issue":"8","key":"2623_CR21","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.3390\/cancers12082131","volume":"12","author":"SE Franks","year":"2020","unstructured":"Franks SE, Wolfson B, Hodge JW. Natural Born Killers: NK Cells in Cancer Therapy. Cancers (Basel), 2020,12(8):2131","journal-title":"Cancers (Basel)"},{"key":"2623_CR22","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.3389\/fimmu.2018.02499","volume":"9","author":"K Ohl","year":"2018","unstructured":"Ohl K, Tenbrock K. Reactive Oxygen Species as Regulators of MDSC-Mediated Immune Suppression. Front Immunol, 2018,9:2499","journal-title":"Front Immunol"},{"key":"2623_CR23","doi-asserted-by":"publisher","first-page":"7307","DOI":"10.2147\/CMAR.S210545","volume":"11","author":"E Chai","year":"2019","unstructured":"Chai E, Zhang L, Li C. LOX-1+ PMN-MDSC enhances immune suppression which promotes glioblastoma multiforme progression. Cancer Manag Res, 2019,11:7307\u20137315","journal-title":"Cancer Manag Res"},{"issue":"1","key":"2623_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.tips.2018.10.008","volume":"40","author":"RJ Tesi","year":"2019","unstructured":"Tesi RJ. MDSC; the Most Important Cell You Have Never Heard Of. Trends Pharmacol Sci, 2019,40(1):4\u20137","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"2623_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00262-013-1508-5","volume":"63","author":"C Meyer","year":"2014","unstructured":"Meyer C, Cagnon L, Costa-Nunes CM, et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother, 2014,63(3):247\u2013257","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"2623_CR26","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1172\/JCI80005","volume":"125","author":"D Marvel","year":"2015","unstructured":"Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest, 2015,125(9):3356\u20133364","journal-title":"J Clin Invest"},{"key":"2623_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fonc.2013.00049","volume":"3","author":"YG Najjar","year":"2013","unstructured":"Najjar YG, Finke JH. Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol, 2013,3:49","journal-title":"Front Oncol"},{"issue":"1","key":"2623_CR28","doi-asserted-by":"publisher","first-page":"240","DOI":"10.4049\/jimmunol.182.1.240","volume":"182","author":"H Li","year":"2009","unstructured":"Li H, Han Y, Guo Q, et al. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol, 2009,182(1):240\u2013249","journal-title":"J Immunol"},{"issue":"2","key":"2623_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/cancers13020309","volume":"13","author":"S Angelicola","year":"2021","unstructured":"Angelicola S, Ruzzi F, Landuzzi L, et al. IFN-\u03b3 and CD38 in Hyperprogressive Cancer Development. Cancers (Basel), 2021,13(2):309","journal-title":"Cancers (Basel)"},{"issue":"2PtC","key":"2623_CR30","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.molimm.2015.10.019","volume":"68","author":"P Sarmadi","year":"2015","unstructured":"Sarmadi P, Tunali G, Esendagli-Yilmaz G, et al. CRAM-A indicates IFN-\u03b3-associated inflammatory response in breast cancer. Mol Immunol, 2015,68(2 Pt C):692\u2013698","journal-title":"Mol Immunol"},{"key":"2623_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jss.2019.02.038","volume":"240","author":"D Imai","year":"2019","unstructured":"Imai D, Yoshizumi T, Okano S, et al. IFN-\u03b3 Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer. J Surg Res, 2019,240:115\u2013123","journal-title":"J Surg Res"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-022-2623-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-022-2623-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-022-2623-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T04:27:11Z","timestamp":1666758431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-022-2623-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["2623"],"URL":"https:\/\/doi.org\/10.1007\/s11596-022-2623-3","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"19 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The corresponding author states that there is no conflict of interest on behalf of all authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}}]}}